Esophageal carcinoma: Towards targeted therapies
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with esophageal cancer are confronted with high mortality rates. Whether it is esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EAC), patients usually present at advanced stages, with treatment options traditionally involving chemotherapy in metastatic settings. With the comprehensive genomic characterization of esophageal cancers, targeted therapies are gaining interest and agents such as ramucirumab, trastuzumab and pembrolizumab are already being used for the treatment of EAC. CONCLUSIONS: Pembrolizumab has recently been FDA-approved for PD-L1 positive, locally advanced or metastatic ESCC. Despite comprehensive molecular characterization, however, available targed therapies for ESCC are still lagging behind. Herein, we discuss current trends towards more targeted therapies in esophageal cancers, taking into consideration unique features of ESCCs and EACs. Patients progressing on standard therapies should be subjected to genomic profiling and considered for clinical trials aimed at testing targeted therapies. Future targeted therapies may include CDK4/6 inhibitors, PARP inhibitors and inhibitors targeting the NRF2 and Wnt signaling pathways. Ultimately, optimized biomarker assays and next generation sequencing platforms may allow for the identification of subcategories of ESCC and EAC patients that will benefit from selective targeted therapies and/or combinations thereof.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, squamous carcinoma is the most common pathogenic form of esophageal cancer in China [18].Its growth rate and pathological changes are diferent from those of adenocarcinoma [19], so the patient may experience diverse symptoms and thus interpret them variously.”
From Symptom Experiences before Medical Help-Seeking and Psychosocial Responses of Patients with Esophageal Cancer: A Qualitative Study. (2023) · cites this paper as [19]
Citations
Cites
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00040-6 · Cited by 2,565
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Kang, Y.-K., Boku, N., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31827-5 · Cited by 2,252
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Cooper, J. S., Guo, M. D., Herskovic, A., Macdonald, J. S., Martenson, Jr., Al-Sarraf, M., Byhardt, R., Russell, A. H., Beitler, J. J., Spencer, S., et al. (1999) · JAMA · doi:10.1001/jama.281.17.1623 · Cited by 1,957
A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma
Walsh, T. N., Noonan, N., Hollywood, D., Kelly, A., Keeling, N., & Hennessy, T. P. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350702 · Cited by 1,950
Integrated genomic characterization of oesophageal carcinoma
The Cancer Genome Atlas Research Network (2017) · Nature · doi:10.1038/nature20805 · Cited by 1,821
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
Epidemiology of Esophageal Squamous Cell Carcinoma
Abnet, C. C., Arnold, M., & Wei, W.-Q. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.08.023 · Cited by 1,672
Tepper, J., Krasna, M. J., Niedzwiecki, D., Hollis, D., Reed, C. E., Goldberg, R., Kiel, K., Willett, C., Sugarbaker, D., & Mayer, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9593 · Cited by 1,352
Shitara, K., Özgüroğlu, M., Bang, Y.-J., Di Bartolomeo, M., Mandalà, M., Ryu, M.-H., Fornaro, L., Olesiński, T., Caglevic, C., Chung, H. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31257-1 · Cited by 1,296
Gebski, V., Burmeister, B., Smithers, B. M., Foo, K., Zalcberg, J., & Simes, J. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70039-6 · Cited by 1,158
Lagergren, J., Smyth, E., Cunningham, D., & Lagergren, P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31462-9 · Cited by 1,141
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Lordick, F., Mariette, C., Haustermans, K., Obermannová, R., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw329 · Cited by 1,098
Identification of genomic alterations in oesophageal squamous cell cancer
Song, Y., Li, L., Ou, Y., Gao, Z., Li, E., Li, X., Zhang, W., Wang, J., Xu, L., Zhou, Y., et al. (2014) · Nature · doi:10.1038/nature13176 · Cited by 1,083
Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Chao, J., Corvera, C., Das, P., Denlinger, C. S., Enzinger, P. C., Fanta, P., Farjah, F., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0033 · Cited by 1,059
Luchini, C., Bibeau, F., Ligtenberg, M. J. L., Singh, N., Nottegar, A., Bosse, T., Miller, R., Riaz, N., Douillard, J.-Y., Andre, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz116 · Cited by 1,041
Smyth, E. C., Lagergren, J., Fitzgerald, R. C., Lordick, F., Shah, M. A., Lagergren, P., & Cunningham, D. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.48 · Cited by 1,012
Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation
Wakabayashi, N., Itoh, K., Wakabayashi, J., Motohashi, H., Noda, S., Takahashi, S., Imakado, S., Kotsuji, T., Otsuka, F., Roop, D. R., et al. (2003) · Nature Genetics · doi:10.1038/ng1248 · Cited by 883
Esophageal cancer: Risk factors, genetic association, and treatment
Huang, F.-L., & Yu, S.-J. (2018) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2016.10.005 · Cited by 874
Rice, T. W., Patil, D. T., & Blackstone, E. H. (2017) · Annals of Cardiothoracic Surgery · doi:10.21037/acs.2017.03.14 · Cited by 782
Dulak, A. M., Stojanov, P., Peng, S., Lawrence, M. S., Fox, C., Stewart, C., Bandla, S., Imamura, Y., Schumacher, S. E., Shefler, E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2591 · Cited by 735
Waddell, T., Chau, I., Cunningham, D., Gonzalez, D., Okines, A. F. C., Wotherspoon, A., Saffery, C., Middleton, G., Wadsley, J., Ferry, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70096-2 · Cited by 725
Genetic landscape of esophageal squamous cell carcinoma
Gao, Y.-B., Chen, Z.-L., Li, J.-G., Hu, X.-D., Shi, X.-J., Sun, Z.-M., Zhang, F., Zhao, Z.-R., Li, Z.-T., Liu, Z.-Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.3076 · Cited by 694
Mavaddat, N., Barrowdale, D., Andrulis, I. L., Domchek, S. M., Eccles, D., Nevanlinna, H., Ramus, S. J., Spurdle, A., Robson, M., Sherman, M., et al. (2012) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0775 · Cited by 669
Rüdiger Siewert, J., Feith, M., Werner, M., & Stein, H. J. (2000) · Annals of Surgery · doi:10.1097/00000658-200009000-00007 · Cited by 662
Genomic and molecular characterization of esophageal squamous cell carcinoma
Lin, D.-C., Hao, J.-J., Nagata, Y., Xu, L., Shang, L., Meng, X., Sato, Y., Okuno, Y., Varela, A. M., Ding, L.-W., et al. (2014) · Nature Genetics · doi:10.1038/ng.2935 · Cited by 626
Hecht, J. R., Bang, Y.-J., Qin, S. K., Chung, H. C., Xu, J. M., Park, J. O., Jeziorski, K., Shparyk, Y., Hoff, P. M., Sobrero, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6598 · Cited by 624
Janjigian, Y. Y., Bendell, J., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Ott, P. A., Peltola, K., Jaeger, D., Evans, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6212 · Cited by 624
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2
Kitagawa, Y., Uno, T., Oyama, T., Kato, K., Kato, H., Kawakubo, H., Kawamura, O., Kusano, M., Kuwano, H., Takeuchi, H., et al. (2019) · Esophagus · doi:10.1007/s10388-018-0642-8 · Cited by 569
Thuss-Patience, P. C., Shah, M. A., Ohtsu, A., Van Cutsem, E., Ajani, J. A., Castro, H., Mansoor, W., Chung, H. C., Bodoky, G., Shitara, K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30111-0 · Cited by 547
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1
Kitagawa, Y., Uno, T., Oyama, T., Kato, K., Kato, H., Kawakubo, H., Kawamura, O., Kusano, M., Kuwano, H., Takeuchi, H., et al. (2019) · Esophagus · doi:10.1007/s10388-018-0641-9 · Cited by 519
Bang, Y.-J., Ruiz, E. Y., Van Cutsem, E., Lee, K.-W., Wyrwicz, L., Schenker, M., Alsina, M., Ryu, M.-H., Chung, H.-C., Evesque, L., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy264 · Cited by 501
Shah, M. A., Kojima, T., Hochhauser, D., Enzinger, P., Raimbourg, J., Hollebecque, A., Lordick, F., Kim, S.-B., Tajika, M., Kim, H. T., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5441 · Cited by 496
Tabernero, J., Hoff, P. M., Shen, L., Ohtsu, A., Shah, M. A., Cheng, K., Song, C., Wu, H., Eng-Wong, J., Kim, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30481-9 · Cited by 490
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420
the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Secrier, M., Li, X., de Silva, N., Eldridge, M. D., Contino, G., Bornschein, J., MacRae, S., Grehan, N., O'Donovan, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3659 · Cited by 405
Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population
Sawada, G., Niida, A., Uchi, R., Hirata, H., Shimamura, T., Suzuki, Y., Shiraishi, Y., Chiba, K., Imoto, S., Takahashi, Y., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.035 · Cited by 332
Esophageal and Esophagogastric Junction Cancers
Ajani, J. A., Barthel, J. S., Bentrem, D. J., D'Amico, T. A., Das, P., Denlinger, C. S., Fuchs, C. S., Gerdes, H., Glasgow, R. E., Hayman, J. A., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0072 · Cited by 331
Zhang, L., Zhou, Y., Cheng, C., Cui, H., Cheng, L., Kong, P., Wang, J., Li, Y., Chen, W., Song, B., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.02.017 · Cited by 329
Boku, N., Ryu, M.-H., Kato, K., Chung, H. C., Minashi, K., Lee, K.-W., Cho, H., Kang, W. K., Komatsu, Y., Tsuda, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy540 · Cited by 312
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival
Gorrini, C., Baniasadi, P. S., Harris, I. S., Silvester, J., Inoue, S., Snow, B., Joshi, P. A., Wakeham, A., Molyneux, S. D., Martin, B., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121337 · Cited by 289
Chang, J., Tan, W., Ling, Z., Xi, R., Shao, M., Chen, M., Luo, Y., Zhao, Y., Liu, Y., Huang, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15290 · Cited by 248
the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Frankell, A. M., Jammula, S., Li, X., Contino, G., Killcoyne, S., Abbas, S., Perner, J., Bower, L., Devonshire, G., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0331-5 · Cited by 231
Shibata, T., Kokubu, A., Saito, S., Narisawa-Saito, M., Sasaki, H., Aoyagi, K., Yoshimatsu, Y., Tachimori, Y., Kushima, R., Kiyono, T., et al. (2011) · Neoplasia · doi:10.1593/neo.11750 · Cited by 224
Fashoyin-Aje, L., Donoghue, M., Chen, H., He, K., Veeraraghavan, J., Goldberg, K. B., Keegan, P., McKee, A. E., & Pazdur, R. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0221 · Cited by 215
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
Schettini, F., De Santo, I., Rea, C. G., De Placido, P., Formisano, L., Giuliano, M., Arpino, G., De Laurentiis, M., Puglisi, F., De Placido, S., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00608 · Cited by 201
Qin, H.-D., Liao, X., Chen, Y., Huang, S.-Y., Xue, W., Li, F.-F., Ge, X.-S., Liu, D.-Q., Cai, Q., Long, J., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.02.021 · Cited by 159
Yan, T., Cui, H., Zhou, Y., Yang, B. J., Kong, P., Zhang, Y., Liu, Y., Wang, B., Cheng, Y., Li, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09255-1 · Cited by 155
Cheng, C., Zhou, Y., Li, H., Xiong, T., Li, S. C., Bi, Y., Kong, P., Wang, F., Cui, H., Li, Y., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.12.013 · Cited by 150
Bang, Y.-J., Cho, J. Y., Kim, Y. H., Kim, J. W., Di Bartolomeo, M., Ajani, J. A., Yamaguchi, K., Balogh, A., Sanchez, T., & Moehler, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0025 · Cited by 142
The role of neoantigen in immune checkpoint blockade therapy
Yi, M., Qin, S., Zhao, W., Yu, S., Chu, Q., & Wu, K. (2018) · Experimental Hematology & Oncology · doi:10.1186/s40164-018-0120-y · Cited by 131
Wagner, D., Grabsch, H. I., Mauer, M. E. L., Marreaud, S. I., Caballero, C. A., Thuss-Patience, P. C., Mueller, L., Elme, A., Moehler, M. H., Martens, U. M., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5675-4 · Cited by 126
Deng, J., Chen, H., Zhou, D., Zhang, J., Chen, Y., Liu, Q., Ai, D., Zhu, H., Chu, L., Ren, W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01730-x · Cited by 120
Recent advances in the clinical development of immune checkpoint blockade therapy
Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 114
ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma
Hazawa, M., Lin, D.-C., Handral, H. K., Xu, L., Chen, Y., Yy, J., Mayakonda, A., Ding, L.-W., Meng, X., Sharma, A., et al. (2016) · Oncogene · doi:10.1038/onc.2016.377 · Cited by 112
Outcomes in the management of esophageal cancer
Paul, S., & Altorki, N. K. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23759 · Cited by 87
Integrative network analysis of TCGA data for ovarian cancer
Zhang, Q., Burdette, J. E., & Wang, J.-P. (2014) · BMC Systems Biology · doi:10.1186/s12918-014-0136-9 · Cited by 85
WNT10A promotes an invasive and self-renewing phenotype in esophageal squamous cell carcinoma
Long, A., Giroux, V., Whelan, K. A., Hamilton, K. E., Tétreault, M.-P., Tanaka, K., Lee, J., Klein–Szanto, A. J., Nakagawa, H., & Rustgi, A. K. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv025 · Cited by 77
Kawasaki, Y., Okumura, H., Uchikado, Y., Kita, Y., Sasaki, K., Owaki, T., Ishigami, S., & Natsugoe, S. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3600-2 · Cited by 69
Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
Robson, M. E., Goessl, C. D., & Domchek, S. M. (2017) · PubMed · doi:10.1056/nejmc1711644 · Cited by 69
Chen, L., & Pan, J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13836 · Cited by 60
Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target
Ma, S., Paiboonrungruan, C., Yan, T., Williams, K. P., Major, M. B., & Chen, X. L. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13681 · Cited by 57
Targeted therapies in gastroesophageal cancer
Kasper, S., & Schüler, M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.009 · Cited by 54
The emerging role of immunotherapy for esophageal cancer
Kelly, R. J. (2019) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000542 · Cited by 48
Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway
Seervi, M., Sumi, S., Chandrasekharan, A., Sharma, A. K., & Santhoshkumar, T. R. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00451-1 · Cited by 47
Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus
Moyes, L. H., McEwan, H., Radulescu, S., Pawlikowski, J. S., Lamm, C. G., Nixon, C., Sansom, O. J., Going, J. J., Fullarton, G. M., & Adams, P. D. (2012) · The Journal of Pathology · doi:10.1002/path.4058 · Cited by 46
Harmonization of PD-L1 Testing in Oncology: A Canadian Pathology Perspective
Ionescu, D. N., Downes, M. R., Christofides, A., & Tsao, M. (2018) · Current Oncology · doi:10.3747/co.25.4031 · Cited by 45
Zhang, J., Jiao, Q., Kong, L., Yu, J., Fang, A., Li, M., & Yu, J. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12640 · Cited by 40
Mizumoto, A., Ohashi, S., Kamada, M., Saito, T., Nakai, Y., Baba, K., Hirohashi, K., Mitani, Y., Kikuchi, O., Matsubara, J., et al. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01549-x · Cited by 35
Targeting the Wnt signaling pathway to treat Barrett’s esophagus
Clément, G., Jablons, D. M., & Benhattar, J. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.3.375 · Cited by 33
Metges, J., François, É., Shah, M. A., Adenis, A., Enzinger, P. C., Kojima, T., Muro, K., Bennouna, J., Hsu, C., Moriwaki, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz154.011 · Cited by 32
Biologic therapy in esophageal and gastric malignancies: current therapies and future directions
Samson, P. P., & Lockhart, A. C. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.11.13 · Cited by 28
Lyros, O., Rafiee, P., Nie, L., Medda, R., Jovanović, N., Otterson, M. F., Behmaram, B., Gockel, I., Mackinnon, A. C., & Shaker, R. (2015) · Neoplasia · doi:10.1016/j.neo.2015.07.006 · Cited by 26
Nuclear localization of PD-L1: artifact or reality?
Polioudaki, H., Chantziou, A., Kalyvianaki, K., Malamos, P., Notas, G., Mavroudis, D., Kampa, M., Castanas, E., & Theodoropoulos, P. A. (2019) · Cellular Oncology · doi:10.1007/s13402-018-00419-7 · Cited by 25
Xiong, T., Wang, M., Zhao, J., Liu, Q., Yang, C., Luo, W., Li, X., Yang, H., Kristiansen, K., Roy, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17989 · Cited by 21
Epigenetic Inactivation of Wnt Inhibitory Factor-1 in Human Esophageal Squamous Cell Carcinoma
Yang, S., Li, S., Dong, Z., & Kan, Q. (2012) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504012x13477145153039 · Cited by 19
Lin, M.-Q., Li, Y., Wu, S., Sun, J., Lin, H.-X., Zhang, S., & He, Z. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s112038 · Cited by 18
Miyamoto, K., Minegaki, T., Tanahashi, M., Yamamoto, A., MORIYAMA, Y., WADA, A., MATSUMOTO, A., OTA, K., Tanaka, M., MASUDA, U., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13288 · Cited by 18
Deng, J., Weng, X., Ye, J., Zhou, D., Liu, Y., & Zhao, K. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00047 · Cited by 17
Dai, J. Y., Wang, X., Buas, M. F., Zhang, C., Ma, J., Wei, B., Li, Y., Zhao, B., Hyun, T. S., Chen, X., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0182-8 · Cited by 15
Research works printed but not linked: 1
- Available from: https://www.ascopost.com/issues/april-10-2019-supplement-conference-highlights-gugi-2019/keynote-181-in-esophageal-cancer/. Accessed 19 October 2019
Cited by
Advances in targeted therapy for esophageal cancer
Yang, Y.-M., Hong, P., Xu, W. W., He, Q.-Y., & Li, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00323-3 · Cited by 508
New insights into the interplay between long non‐coding RNAs and RNA‐binding proteins in cancer
Yao, Z., Yang, Y., Sun, M., He, Y., Liao, L., Chen, K., & Li, B. (2022) · Cancer Communications · doi:10.1002/cac2.12254 · Cited by 288
Advances and challenges in the treatment of esophageal cancer
He, S., Xu, J., Liu, X., & Zhen, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.008 · Cited by 287
m6A Reader HNRNPA2B1 Promotes Esophageal Cancer Progression via Up-Regulation of ACLY and ACC1
Guo, H., Wang, B., Xu, K., Nie, L., Fu, Y. S., Wang, Z., Wang, Q., Wang, S., & Zou, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.553045 · Cited by 140
Zhu, P., Yu, H., Zhou, K., Bai, Y., Qi, R., & Zhang, S. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01618-7 · Cited by 57
Metadata
- Authors
- Fatehi Hassanabad, A., Chehade, R., Breadner, D., & Raphael, J.
- Affiliations
- Western University (CA)
- Venue
- Cellular Oncology
- Published
- 2019-12-17
- Volume
- 43
- Issue
- 2
- Pages
- 195-209
- ISSN
- 1570-5870 (ISSN-L)
- 2211-3428
- 2211-3436
- PMC
- PMC12990719
- OpenAlex
- W2994654968
- Cited by
- 158
- References
- 83
- Citations by year
- 2026: 5 · 2025: 17 · 2024: 29 · 2023: 20 · 2022: 44 · 2021: 29 · 2020: 14
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Cellular Oncology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- esophageal squamous cell carcinoma, esophageal adenocarcinoma, targeted therapy, pembrolizumab, PD-L1, ramucirumab, trastuzumab, CDK4/6 inhibitors, PARP inhibitors, Nrf2 signaling, Wnt signaling, genomic profiling, biomarkers, metastatic esophageal cancer
- MeSH terms
- Adenocarcinoma, Carcinoma, Squamous Cell, Enzyme Inhibitors, Esophageal Neoplasms, Humans, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Molecular Targeted Therapy, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.